K-numberK243837
Device nameiBSM
ApplicantIorbit Digital Technologies Private Limited
Product codeDRG
Device classClass II
Decision dateMay 16, 2025
DecisionSubstantially Equivalent
Regulation870.2910
AI Summary extracted from FDA summary PDF · never regenerated
Intended use

The iBSM is a wireless patient monitoring system for general care hospital patients (18+ years) that continuously displays ECG waveforms, heart rate, respiratory rate, SpO2, skin temperature, blood pressure, body position, and fall detection. It is not intended for critical care, home use, ICU/CCU, or surgery rooms, and operates through wearable sensors paired with a tablet application that transmits data to an external server.

Technological characteristics

The iBSM uses third-party FDA-cleared wearable sensors (ANNE Chest and ANNE Limb from Sibel Health) paired with an iBSM View application running on Android 12 tablets with a docking station. It communicates internally via Bluetooth LE and externally via WiFi LAN. Performance specifications match the predicate: HR range 30–270 bpm (±5 bpm or ±10%), RR 8–35 brpm (±3 brpm), SpO2 70–100% (±3% ARMS), temperature 73.2–109.4°F (±0.54°F), NIBP 0–300 mmHg (±3 mmHg).

Test standards cited

IEC 60601-1:2005+AMD1:2012+AMD2:2020, IEC 60601-1-2:2014, IEC 60601-1-6:2010, IEC 60601-1-8:2006, IEC 60601-2-27, IEC 60601-2-47, IEC 80601-2-30, IEC 80601-2-49, ISO 80601-2-56:2017, ISO 80601-2-61:2017, IEC 62304:2015, ANSI C63.27, ISO 10993-5:2009, ISO 10993-10:2021, and ASTM D4169.

Substantial equivalence argument

iBSM is substantially equivalent to ANNE One (K223711) because it measures identical physiological parameters (ECG, HR, RR, SpO2, temperature, body position, fall detection) using the same type of third-party FDA-cleared sensors with matching performance specifications and accuracy ranges. Both are Class II devices regulated under 21 CFR 870.2910, use identical wireless communication (Bluetooth LE and WiFi), undergo the same safety and performance testing standards, and are designed for general care patient monitoring in hospital settings. The primary difference—iBSM restricts use to healthcare settings only while ANNE One permits home use—does not alter the fundamental technology or safety profile of the monitoring function itself.

Extracted by AI from the official FDA summary PDF →
Source

View the full FDA submission: accessdata.fda.gov

Researching this as a predicate?
Want a transparent AI-ranking score, AI-discovered related predicates, ongoing safety and warning-letter monitoring, full predicate chain lineage, and a drafted SE rationale — all saved to your own project? That's what an account adds.
Start free trial →

Everything you need for a 510(k) submission. Nothing you don't.

14-day free trial. No setup. Cancel anytime.

Start free trial →
Building an AI or ML-enabled device? Predicate search, PCCP tracking, and AI-specific FDA intelligence — built exclusively for AI/ML devices. Try AIFDA Intel →